Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma
1996

Chimeric Bispecific Antibody to Treat Kidney Cancer

publication Evidence: moderate

Author Information

Author(s): RM Luiten, LR Coney, GJ Fleuren, SO Warnaarl, SV Litvinov

Primary Institution: Department of Pathology, University of Leiden

Hypothesis

The chimeric bispecific G250/anti-CD3 monoclonal antibody can effectively target and lyse renal cell carcinoma cells.

Conclusion

The chimeric bispecific G250/anti-CD3 MAb can induce lysis of renal cell carcinoma cells by human T cells at very low concentrations.

Supporting Evidence

  • The chimeric bispecific antibody was capable of mediating lysis of RCC cell lines by human T cells.
  • Lysis was specific for target cells expressing the G250 antigen.
  • The chimeric bispecific G250/anti-CD3 MAb was effective at concentrations as low as 0.01 pg/ml.

Takeaway

Scientists created a special antibody that can help the body's immune cells attack kidney cancer cells better.

Methodology

The study involved generating a chimeric bispecific antibody and testing its ability to mediate lysis of renal cell carcinoma cells in vitro using human T cells.

Limitations

The study primarily involved in vitro experiments, and the effectiveness in vivo remains to be fully evaluated.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication